image
Healthcare - Medical - Devices - NASDAQ - US
$ 61.63
3.01 %
$ 24.1 B
Market Cap
43.4
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one DXCM stock under the worst case scenario is HIDDEN Compared to the current market price of 61.6 USD, DexCom, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one DXCM stock under the base case scenario is HIDDEN Compared to the current market price of 61.6 USD, DexCom, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one DXCM stock under the best case scenario is HIDDEN Compared to the current market price of 61.6 USD, DexCom, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart DXCM

image
$95.0$95.0$90.0$90.0$85.0$85.0$80.0$80.0$75.0$75.0$70.0$70.0$65.0$65.0$60.0$60.0$55.0$55.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
4.03 B REVENUE
11.34%
600 M OPERATING INCOME
0.38%
576 M NET INCOME
6.41%
990 M OPERATING CASH FLOW
32.20%
-208 M INVESTING CASH FLOW
59.09%
-735 M FINANCING CASH FLOW
-130.63%
1.11 B REVENUE
12.00%
189 M OPERATING INCOME
24.28%
152 M NET INCOME
12.70%
301 M OPERATING CASH FLOW
51.08%
-304 M INVESTING CASH FLOW
-144.41%
-1.6 M FINANCING CASH FLOW
99.78%
Balance Sheet DexCom, Inc.
image
Current Assets 4.3 B
Cash & Short-Term Investments 2.58 B
Receivables 1.01 B
Other Current Assets 716 M
Non-Current Assets 2.18 B
Long-Term Investments 0
PP&E 1.4 B
Other Non-Current Assets 780 M
39.78 %15.51 %11.05 %21.63 %12.03 %Total Assets$6.5b
Current Liabilities 2.93 B
Accounts Payable 1.59 B
Short-Term Debt 1.23 B
Other Current Liabilities 120 M
Non-Current Liabilities 1.45 B
Long-Term Debt 1.3 B
Other Non-Current Liabilities 148 M
36.17 %28.00 %29.71 %3.38 %Total Liabilities$4.4b
EFFICIENCY
Earnings Waterfall DexCom, Inc.
image
Revenue 4.03 B
Cost Of Revenue 1.57 B
Gross Profit 2.47 B
Operating Expenses 1.87 B
Operating Income 600 M
Other Expenses 23.8 M
Net Income 576 M
5b5b4b4b4b4b3b3b3b3b2b2b2b2b1b1b500m500m004b(2b)2b(2b)600m(24m)576mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
61.14% GROSS MARGIN
61.14%
14.88% OPERATING MARGIN
14.88%
14.29% NET MARGIN
14.29%
27.40% ROE
27.40%
8.89% ROA
8.89%
10.20% ROIC
10.20%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis DexCom, Inc.
image
700m700m600m600m500m500m400m400m300m300m200m200m100m100m0020162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 576 M
Depreciation & Amortization 218 M
Capital Expenditures -359 M
Stock-Based Compensation 170 M
Change in Working Capital 0
Others 25.2 M
Free Cash Flow 631 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets DexCom, Inc.
image
Wall Street analysts predict an average 1-year price target for DXCM of $119 , with forecasts ranging from a low of $89 to a high of $150 .
DXCM Lowest Price Target Wall Street Target
89 USD 44.41%
DXCM Average Price Target Wall Street Target
119 USD 93.83%
DXCM Highest Price Target Wall Street Target
150 USD 143.39%
Price
Max Price Target
Min Price Target
Average Price Target
15015014014013013012012011011010010090908080707060605050May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 11
6. Ownership
Insider Ownership DexCom, Inc.
image
Sold
0-3 MONTHS
9.96 M USD 7
3-6 MONTHS
806 K USD 4
6-9 MONTHS
296 K USD 5
9-12 MONTHS
1.85 M USD 7
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now DXCM continues to raise investor optimism due to its strong product portfolio. zacks.com - 2 weeks ago
Dexcom Schedules First Quarter 2025 Earnings Release and Conference Call for May 1, 2025 at 4:30 p.m. Eastern Time. SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2025 financial results after market close on Thursday, May 1, 2025. Management will hold a conference call to review the company's first quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be. businesswire.com - 2 weeks ago
Government of Saskatchewan Expands Public Coverage for Dexcom Continuous Glucose Monitoring Systems BURNABY, British Columbia--(BUSINESS WIRE)--The Government of Saskatchewan expands public coverage for Dexcom Continuous Glucose Monitoring Systems. businesswire.com - 2 weeks ago
DXCM Inks Deal With Nanowear to Boost CGM Application Beyond Diabetes DexCom's recent licensing deal with Nanowear is likely to reinforce the broader potential of CGMs in continuous metabolic health monitoring. zacks.com - 2 weeks ago
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 Approval DexCom receives a warning letter from the FDA citing several issues with its popular G6 & G7 sensor manufacturing. The company response is inadequate. zacks.com - 3 weeks ago
DXCM Stock Gains Following New Data on Upcoming G7 CGM Sensor DexCom plans to launch its 15-day G7 sensor in the second half of 2025, pending FDA approval. A longer wear time may boost competitive advantage. zacks.com - 3 weeks ago
Dexcom Appoints Jon Coleman as Chief Commercial Officer SAN DIEGO--(BUSINESS WIRE)--Dexcom Appoints Jon Coleman as Chief Commercial Officer. businesswire.com - 3 weeks ago
Nanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With Dexcom NEW YORK--(BUSINESS WIRE)--Nanowear, a leader in home-based cardiometabolic digital diagnostics announced that SimpleSenseā„¢, a nanotechnology-enabled wearable, mobile and software diagnostics platform, will ingest glucose data from Dexcom G7 Continuous Glucose Monitoring Systems (CGM) time synchronously alongside Nanowear's previously FDA cleared cardiovascular biomarkers. The continuous combination of glucose readings, blood pressure, ECGs, lung volume, respiration and hemodynamics offer unpre. businesswire.com - 3 weeks ago
Nasdaq Sell-Off: 2 Brilliant Stocks to Buy No Matter What the Market Does Next Equity markets started 2025 pretty well, but things haven't been so rosy in the past couple of months. The tech-heavy Nasdaq Composite index is down by 8% since the beginning of the year as I write this. fool.com - 1 month ago
Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medication for Future of Type 2 Care EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of Type 2 Report: Access and Attitudes Across Europe and the Middle East." The report surveyed over 2,500 people, made up of individuals with Type 2 diabetes and healthcare professionals, from Germany, Italy, the Netherlands, Saudi Arabia, Spain and the United Kingdom. The findings provide valuable in. businesswire.com - 1 month ago
DexCom CGM Sensor Sales to Continue Despite FDA Warning Letter DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising competition pose challenges. zacks.com - 1 month ago
History Says Shut Up And Buy: 12 Hyper-Growth Blue Chips To Buy Right Now Market corrections, like the recent dip, are normal and temporary, with historical data showing average declines of 13-14% since 1950. Long-term investors should stay the course. Corrections often lead to robust recoveries, with historical returns averaging 25% in the year following volatility like the one we just experienced. Asset allocation, not market timing, is key. A balanced portfolio of stocks and bonds has historically minimized risk and delivered consistent returns. seekingalpha.com - 1 month ago
8. Profile Summary

DexCom, Inc. DXCM

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 24.1 B
Dividend Yield 0.00%
Description DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Contact 6340 Sequence Drive, San Diego, CA, 92121 https://www.dexcom.com
IPO Date April 14, 2005
Employees 10200
Officers Ms. Sadie M. Stern Executive Vice President & Chief Human Resources Officer Mr. Sean Christensen Vice President of Finance and Investor Relations Mr. Barry J. Regan Executive Vice President of Global Operations Mr. Kevin Ronald Sayer Executive Chairman, Chief Executive Officer & President Mr. Matthew Dolan Executive Vice President of Strategy, Corporate Development & Dexcom Labs Ms. Leverne Marsh Executive Vice President of Marketing Mr. Donald M. Abbey Executive Vice President of Global Business Services, IT, Quality & Regulatory Affairs Mr. Girish Naganathan Executive Vice President & Chief Technology Officer Mr. Michael Jon Brown Executive Vice President & Chief Legal Officer Mr. Jacob Steven Leach Executive Vice President & Chief Operating Officer